PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Anticholinergics - Market size and forecast 2018-2023 Antihistamines - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Advent of nauseogenic information technology Rising trend of virtual reality Growing research in psychosomatic disorders PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Baxter International Inc. GlaxoSmithKline Plc Johnson & Johnson Services Inc. Pfizer Inc. Prestige Consumer Healthcare Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Anticholinergics - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Anticholinergics - Year-over-year growth 2019-2023 (%) Exhibit 22: Antihistamines - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antihistamines - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Dosage forms: An overview Exhibit 43: Impact of drivers and challenges Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: Baxter International Inc. - Vendor overview Exhibit 50: Baxter International Inc. - Business segments Exhibit 51: Baxter International Inc. - Organizational developments Exhibit 52: Baxter International Inc. - Geographic focus Exhibit 53: Baxter International Inc. - Segment focus Exhibit 54: Baxter International Inc. - Key offerings Exhibit 55: Baxter International Inc. - Key customers Exhibit 56: GlaxoSmithKline Plc - Vendor overview Exhibit 57: GlaxoSmithKline Plc - Business segments Exhibit 58: GlaxoSmithKline Plc - Organizational developments Exhibit 59: GlaxoSmithKline Plc - Geographic focus Exhibit 60: GlaxoSmithKline Plc - Segment focus Exhibit 61: GlaxoSmithKline Plc - Key offerings Exhibit 62: GlaxoSmithKline Plc - Key customers Exhibit 63: Johnson & Johnson Services Inc. - Vendor overview Exhibit 64: Johnson & Johnson Services Inc. - Business segments Exhibit 65: Johnson & Johnson Services Inc. - Organizational developments Exhibit 66: Johnson & Johnson Services Inc. - Geographic focus Exhibit 67: Johnson & Johnson Services Inc. - Segment focus Exhibit 68: Johnson & Johnson Services Inc. - Key offerings Exhibit 69: Johnson & Johnson Services Inc. - Key customers Exhibit 70: Pfizer Inc. - Vendor overview Exhibit 71: Pfizer Inc. - Business segments Exhibit 72: Pfizer Inc. - Organizational developments Exhibit 73: Pfizer Inc. - Geographic focus Exhibit 74: Pfizer Inc. - Segment focus Exhibit 75: Pfizer Inc. - Key offerings Exhibit 76: Pfizer Inc. - Key customers Exhibit 77: Prestige Consumer Healthcare Inc. - Vendor overview Exhibit 78: Prestige Consumer Healthcare Inc. - Business segments Exhibit 79: Prestige Consumer Healthcare Inc. - Organizational developments Exhibit 80: Prestige Consumer Healthcare Inc. - Geographic focus Exhibit 81: Prestige Consumer Healthcare Inc. - Segment focus Exhibit 82: Prestige Consumer Healthcare Inc. - Key offerings Exhibit 83: Prestige Consumer Healthcare Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc.